Psychedelic-assisted therapy is making its way through the established medical system’s approval process and moving towards becoming an available treatment for conditions such as PTSD and Depression. This comes after years of prohibition of psychedelics through international drug conventions and local laws often disproportionately enforced in marginalized communities. As states and regulatory bodies consider making psychedelic-assisted therapy available, key social justice considerations come into focus, particularly around healthcare disparities and access to treatment, medicalization of plants that certain communities consider sacred, oppressive psychiatric treatments, and stigma experienced by people who use drugs.
The webinar series will cover a range of topics about both the present challenges and future opportunities for addressing social injustice in the field of psychedelic medicine, focusing on the role of the clinician’s voice in the context of the larger healthcare system. The instructors and panelists will contribute their own unique perspectives and insights into the social justice implications of psychedelic-assisted therapy, research, and treatment. Throughout the series, participants will be encouraged to bring curiosity and openness to their own experiences, with a focus on developing insight and understanding based therein. To encourage ongoing reflection and engagement with the material participants will be invited to complete various exercises to clarify their reaction to the material, what they have learned and how they desire to incorporate these insights into their lives going forward.
- $100 for the 10-webinar series with 10 hours of CE included. Please click “Purchase Webinar Bundle Here” above to purchase the bundle.
- $12 for any individual webinar with 1 hour of CE. Please click on the hyperlinked single sessions below to purchase an individual webinar.
Webinar Topics and Descriptions
Session 1: Rights, Regulations, and Reconciliation: Exploring an Equitable Drug Policy with Kelly Sykes, PhD
This webinar will discuss past and current drug policies with a particular focus on key considerations for providers offering psychedelic integration therapy and who seek to offer psychedelic-assisted therapy in the future.
Background: The prohibition of psychedelics through international drug conventions and local laws are slowly giving way to new regulatory models making psychedelic-assisted therapy available. Past and present enforcement of prohibition has disproportionately affected marginalized communities, and ongoing disparities in care and access to treatment continue to be key considerations in psychedelic-assisted therapy.
Session 2: Challenges of Mainstreaming Psychedelic-assisted Therapies: A Critical Analysis of the Mental Health Model with Guest Speaker Tehseen Noorani, PhD
As psychedelic therapy gains broad public attention, the ascendant model proposed is largely a medical/mental health model. In this session, we will discuss the limitations and challenges of the medicalization of psychedelic therapy.
Session 3: Cultural Elevation of Sanity and Abstinence and Implications for Psychedelic Assisted Therapy with Kelly Sykes, PhD
This webinar will explore mainstream discourse in the West, and will critically analyze the elevation and devaluation of certain states of consciousness. We will consider ways in which the marginalization of alternative perspectives on topics such as sanity and drug abstinence influence current treatment models, and we will explore how psychedelics provide opportunities to create alternative models.
Session 4: Inclusion in Psychedelic-assisted therapy: Racial disparities in research, Racial Trauma, Race as Part of Set and Setting with Guest Speaker Joseph McCowan, Psy.D
The BIPOC community continues to be underrepresented as both providers and potential clients in psychedelic therapy research, which can lead to broad gaps in and misunderstandings of what we consider “evidence-based treatment.” This session will explore what current research tells us about the inclusion of people of color in psychedelic-assisted psychotherapy and address how experiences of race and racial trauma can influence psychedelic experiences.
Session 5, 2021: Challenges to Challenging the Status Quo in Psychedelic Research and Treatment with Elizabeth Nielson, PhD
As a burgeoning treatment modality, psychedelic-assisted therapy is often discussed as an alternative and challenge to the predominant psychotherapy modality of weekly 45-60 minute sessions. However, many aspects of psychedelic research and treatment are embedded in the same systems as other treatments. This webinar will highlight and elucidate some of the challenges of navigating systems such as embedded economic interests and structures, intellectual property issues around patents and treatments, and difficulties in community outreach and training of culturally informed care.
Session 6: Whose Medicine Is It? Decriminalization, medicalization and infringement on indigenous communities with Guest Speaker Cristie Strongman, Ed.M.
Broadening awareness of the therapeutic benefits of psychedelics has buttressed decriminalization and legalization efforts. As these efforts gain traction, indigenous communities have called attention to their lack of inclusion, and how these efforts potentially threaten the dwindling populations of plants they hold sacred and cultural practices that have been oppressed for centuries. This webinar will highlight some of the challenges and infringements of decriminalization, medicalization, and the phenomenon of “neo-shamanism” on indigenous communities. We will explore the complexities of cultural syncretism vs. appropriation with a particular focus on how Western providers can practice in psychedelic therapy.
Session 7: Inclusive Models of Sexuality and Gender in Psychedelic Assisted Psychotherapy with Jeffrey Guss, MD
The traditional conceptualization of the male-female co-therapy team as the ideal has evolved. This webinar will present early and current conceptualizations of the psychedelic therapy co-therapy team, and explore sex and gender as part of set and setting. Inclusive models of gender in psychedelic-assisted therapy impact all aspects of psychedelic treatment including creation of the co-therapy team, and how to work with clients in preparation, dosage and integration stages of a psychedelic experience.
Session 8: Cultural Attitudes and PTSD: Who Gets Compassionate Care? with Kelly Sykes, PhD
This webinar will examine how cultural values and attitudes impact how and who we treat for Post-Traumatic Stress Disorder. We will explore the attitudes of providers, court systems, and communities towards veterans of foreign wars versus victims of community violence and poverty, and how this impacts how we treat their struggles and who receives psychedelic therapy.
Session 9: Ethical Considerations and Guidelines for an Inclusive Community Practice with Guest Speaker Rebecca Kronman, LCSW
National and international provider organizations have broadly elucidated ethical practice guidelines and codes of conduct for their professional members. However, few have considered unique guidelines or ethics of psychedelic practices. This webinar will discuss current ethical considerations and existing codes of conduct or community guidelines for psychedelic practice.
Session 10: Standing at the Gates: Provider Training, Requirements, and Stigma within Psychedelic Assisted Therapy with Ingmar Gorman, PhD
A consideration in psychedelic-assisted therapy is who administers the treatment. The burgeoning landscape of training and licensing of psychedelic-assisted therapy will have many aspects to consider. Federal prohibition of psychedelics limits trainees’ ability to have firsthand experiences with psychedelics and training models do not require such experiences. Requirements that only licensed professionals may provide such treatment limits broader access to training, devalues the work of indigenous experts, and ignores “underground” practices where many experienced individuals operate. At present, licensed professionals offering psychedelic integration therapy risk stigma and potentially draw scrutiny from their state licensing boards. This webinar will explore current training models, potential licensing requirements for psychedelic therapy, and the stigma attached to providers who operate in this space.